Previous close | 10.46 |
Open | 10.64 |
Bid | 10.47 x 300 |
Ask | 10.53 x 100 |
Day's range | 10.38 - 10.83 |
52-week range | 8.12 - 43.69 |
Volume | |
Avg. volume | 1,006,028 |
Market cap | 378.137M |
Beta (5Y monthly) | -0.35 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.55 |
Earnings date | 01 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 53.00 |
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cellsREDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose exp
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cellsAnnounced initial clinical data from our Phase 2 study (COVALENT-112) in type 1 diabetes from the first two type 1 diabetes patients dosed with BMF-219 and demonstrated ea